Publicaciones en las que colabora con Yolanda Arias Piedras (8)

2013

  1. In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours

    Cancer Immunology, Immunotherapy, Vol. 62, Núm. 3, pp. 541-551

2012

  1. Transient injury-dependent up-regulation of CD105 and its specific targeting with an anti-vascular anti-mouse endoglin-nigrin b immunotoxin

    Medicinal Chemistry, Vol. 8, Núm. 6, pp. 996-1002

2007

  1. Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b

    Cancer Letters, Vol. 256, Núm. 1, pp. 73-80

2005

  1. Cytotoxicity of an ebulin l-anti-human CD105 immunotoxin on mouse fibroblasts (L929) and rat myoblasts (L6E9) cells expressing human CD105.

    Medicinal chemistry, Vol. 1, Núm. 1, pp. 65-70

  2. Specific dose-dependent damage of Lieberkühn crypts promoted by large doses of type 2 ribosome-inactivating protein nigrin b intravenous injection to mice

    Toxicology and Applied Pharmacology, Vol. 207, Núm. 2, pp. 138-146

2004

  1. Utilización de la proteína inactivadora de ribosomas nigrina b en la construcción de inmunotoxinas contra la vasculatura tumoral

    Utilización de la proteína inactivadora de ribosomas nigrina b en la construcción de inmunotoxinas contra la vasculatura tumoral

2003

  1. Non-toxic type 2 ribosome-inactivating proteins (RIPs) from Sambucus: occurrence, cellular and molecular activities and potential uses.

    Cellular and molecular biology (Noisy-le-Grand, France), Vol. 49, Núm. 4, pp. 537-545

2001

  1. Sensitivity of cancer cell lines to the novel non-toxic type 2 ribosome-inactivating protein nigrin b

    Cancer Letters, Vol. 167, Núm. 2, pp. 163-169